The Deep Value Play for Growth Investors Isn't Artificial Intelligence, It's This Forgotten Industry

The article argues that cannabis stocks may offer greater upside than highly valued AI stocks, while warning that AI shares could fall if growth weakens. Curaleaf generated $1.3 billion in trailing-12-month revenue but has lost 73% of its value over five years and has a $2.4 billion market capitalization; the author says it could potentially grow tenfold if reform advances. Federal rescheduling of medical marijuana from Schedule I to Schedule III has been delayed but is still expected, though reform and a stock catalyst are uncertain.

Analysis

The key asymmetry is policy optionality versus execution: cannabis can re-rate sharply on a credible federal change, but a delayed process leaves operators exposed to state-by-state competition and constrained interstate economics. Rescheduling is not equivalent to legalization; verify the final rule, effective date, and tax treatment before underwriting a durable cash-flow step-up. Any benefit may accrue unevenly, so Curaleaf (CURA) revenue scale alone does not establish superior margins, free cash flow, or balance-sheet resilience.

Near term (days to weeks), this article is unlikely to be a catalyst by itself. Over 1–3 months, regulatory milestones and election-related signals matter more than broad reform rhetoric. Over 6–18 months, a confirmed change could improve the sector’s operating and financing environment, but dilution, debt service, and competitive responses could absorb some of the upside. A reversal or further delay would likely keep the sector’s policy discount intact.

The contrarian point: cannabis is not automatically the “value” alternative to AI. The relative trade bundles two unrelated risks, and AI valuation concerns do not create cannabis cash flows. The more defensible view is small, event-driven cannabis exposure rather than a wholesale rotation out of NVDA, PLTR, or AVGO. Do not infer company-specific downside for those names from a sector-level bubble argument.

Key Decisions for Investors

• Treat CURA as a high-risk policy-optionality position, not a proven deep-value compounder. Before sizing, check latest cash flow, debt maturities, share count/dilution, and segment economics; the article does not establish these.
• Use regulatory milestones as entry triggers: add only after a verifiable final rescheduling action and clarity on effective date and tax treatment. A delay, adverse rule, or lack of implementation is a thesis-falsifying signal.
• Avoid a mechanical long-CURA/short-NVDA, PLTR, or AVGO pair. If portfolio exposure to speculative growth is excessive, trim it on valuation and earnings-risk grounds independently; do not rely on cannabis as a hedge.
• Monitor CURA’s operating cash flow, refinancing terms, and share issuance alongside federal and state policy. If policy progress fails to translate into improving cash generation over coming quarters, reassess the re-rating thesis.